From October 2015 to October 2024, 2,429 [68Ga]Ga-PSMA-11 syntheses (5,892 patients’ doses) were produced for clinical applications, including 4,773 doses for PET-CT (81%) and 1,119 for PET-MR (19%) for PCa diagnosis and staging/restaging.(23,24). Here, FOLH1 is linked to posterior cortical atrophy.